Androgen receptor-induced tumor suppressor, KLLN, inhibits breast cancer growth and transcriptionally activates p53/p73-mediated: Apoptosis in breast carcinomas

Human Molecular Genetics

Volumn 22, Issue 11, 2013, Pages 2263-2272

  Wang, Yu ^a   He, Xin ^a   Yu, Qi ^a   Eng, Charis ^a,b,c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b TAUSSIG CANCER INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN P53; PROTEIN P73; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR KLLN; UNCLASSIFIED DRUG;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BREAST CARCINOMA; BREAST METASTASIS; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN DEPLETION; PROTEIN FUNCTION; TRANSCRIPTION INITIATION; TUMOR GROWTH; TUMOR INVASION; TUMOR SUPPRESSOR GENE;

AGED; ANDROGENS; ANIMALS; APOPTOSIS; BREAST NEOPLASMS; CARCINOMA; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; NEOPLASM GRADING; NUCLEAR PROTEINS; RECEPTORS, ANDROGEN; TRANSCRIPTIONAL ACTIVATION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

EID: 84877887765     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddt077     Document Type: Article

References (36)

1. Agoff, S.N., Swanson, P.E., Linden, H., Hawes, S.E. and Lawton, T.J. (2003) Androgen receptor expression in estrogen receptor-negative breastcancer. Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol., 120, 725-731.
2. Ogawa, Y., Hai, E., Matsumoto, K., Ikeda, K., Tokunaga, S., Nagahara, H., Sakurai, K., Inoue, T. and Nishiguchi, Y. (2008) Androgen receptor expression in breast cancer: relationship with clinicopathological factors and biomarkers. Int. J. Clin. Oncol., 13, 431-435.
3. Loibl, S., Muller, B.M., von Minckwitz, G., Schwabe, M., Roller, M., Darb-Esfahani, S., Ataseven, B., du Bois, A., Fissler-Eckhoff, A., Gerber, B. et al. (2011) Androgen receptor expression in primary breast cancer and its predictive and prognostic value in patients treated with neoadjuvant chemotherapy. Breast Cancer Res. Treat., 130, 477-487.
4. Kandouz, M., Lombet, A., Perrot, J.Y., Jacob, D., Carvajal, S., Kazem, A., Rostene, W., Therwath, A. and Gompel, A. (1999) Proapoptotic effects of antiestrogens, progestins and androgen in breast cancer cells. J. Steroid. Biochem. Mol. Biol., 69, 463-471.
5. Kampa, M., Nifli, A.P., Charalampopoulos, I., Alexaki, V.I., Theodoropoulos, P.A., Stathopoulos, E.N., Gravanis, A. and Castanas, E. (2005) Opposing effects of estradiol- and testosterone-membrane binding sites on T47D breast cancer cell apoptosis. Exp. Cell Res., 307, 41-51.
6. Cho, Y.J. and Liang, P. (2008) Killin is a p53-regulated nuclear inhibitor of DNA synthesis. Proc. Natl Acad. Sci. USA, 105, 5396-5401.
7. Bennett, K.L., Mester, J. and Eng, C. (2010) Germline epigenetic regulation of KILLIN in Cowden and Cowden-like syndrome. JAMA, 304, 2724-2731.
8. Wang, Y., Romigh, T., He, X., Tan, M.H., Orloff, M.S., Silverman, R.H., Heston, W.D. and Eng, C. (2011) Differential regulation of PTEN expression by androgen receptor in prostate and breast cancers. Oncogene, 30, 4327-4338.
9. Shirley, S.H., Rundhaug, J.E., Tian, J., Cullinan-Ammann, N., Lambertz, I., Conti, C.J. and Fuchs-Young, R. (2009) Transcriptional regulation of estrogen receptor-alpha by p53 in human breast cancer cells. Cancer Res., 69, 3405-3414.
10. Wang, Y., He, X., Ngeow, J. and Eng, C. (2012) GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. Hum. Mol. Genet., 21, 569-576.
11. Jost, C.A., Marin, M.C. and Kaelin, W.G. Jr. (1997) p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature, 389, 191-194.
12. Kaghad, M., Bonnet, H., Yang, A., Creancier, L., Biscan, J.C., Valent, A., Minty, A., Chalon, P., Lelias, J.M., Dumont, X. et al. (1997) Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell, 90, 809-819.
13. Ando, S., De Amicis, F., Rago, V., Carpino, A., Maggiolini, M., Panno, M.L. and Lanzino, M. (2002) Breast cancer: from estrogen to androgen receptor. Mol. Cell Endocrinol., 193, 121-128.
14. Moore, N.L., Buchanan, G., Harris, J.M., Selth, L.A., Bianco-Miotto, T., Hanson, A.R., Birrell, S.N., Butler, L.M., Hickey, T.E. and Tilley, W.D. (2012) An androgen receptor mutation in the MDA-MB-453 cell line model of molecular apocrine breast cancer compromises receptor activity. Endocr. Relat. Cancer, 19, 599-613.
15. Isola, J.J. (1993) Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol., 170, 31-35.
16. Soreide, J.A., Lea, O.A., Varhaug, J.E., Skarstein, A. and Kvinnsland, S. (1992) Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur. J. Surg. Oncol., 18, 112-118.
17. de Launoit, Y., Dauvois, S., Dufour, M., Simard, J. and Labrie, F. (1991) Inhibition of cell cycle kinetics and proliferation by the androgen 5 alpha-dihydrotestosterone and antiestrogen N,n-butyl-N-methyl-11-[16′ alpha-chloro-3′,17 beta-dihydroxy-estra-1′,3′,5′-(10′)triene-7′alpha-yl] undecanamide in human breast cancer ZR-75-1 cells. Cancer Res., 51, 2797-2802.
18. Lapointe, J. and Labrie, C. (2001) Role of the cyclin-dependent kinase inhibitor p27(Kip1) in androgen-induced inhibition of CAMA-1 breast cancer cell proliferation. Endocrinology, 142, 4331-4338.
19. Macedo, L.F., Guo, Z., Tilghman, S.L., Sabnis, G.J., Qiu, Y. and Brodie, A. (2006) Role of androgens on MCF-7 breast cancer cell growth and on the inhibitory effect of letrozole. Cancer Res., 66, 7775-7782.
20. Peters, A.A., Buchanan, G., Ricciardelli, C., Bianco-Miotto, T., Centenera, M.M., Harris, J.M., Jindal, S., Segara, D., Jia, L., Moore, N.L. et al. (2009) Androgen receptor inhibits estrogen receptor-alpha activity and is prognostic in breast cancer. Cancer Res., 69, 6131-6140.
21. Doane, A.S., Danso, M., Lal, P., Donaton, M., Zhang, L., Hudis, C. and Gerald, W.L. (2006) An estrogen receptor-negative breast cancer subset characterized by a hormonally regulated transcriptional program and response to androgen. Oncogene, 25, 3994-4008.
22. Ni, M., Chen, Y., Lim, E., Wimberly, H., Bailey, S.T., Imai, Y., Rimm, D.L., Liu, X.S. and Brown, M. (2011) Targeting androgen receptor in estrogen receptor-negative breast cancer. Cancer Cell, 20, 119-131.
23. Lehmann, B.D., Bauer, J.A., Chen, X., Sanders, M.E., Chakravarthy, A.B., Shyr, Y. and Pietenpol, J.A. (2011) Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J. Clin. Invest., 121, 2750-2767.
24. Greeve, M.A., Allan, R.K., Harvey, J.M. and Bentel, J.M. (2004) Inhibition of MCF-7 breast cancer cell proliferation by 5alpha-dihydrotestosterone; a role for p21(Cip1/Waf1). J. Mol. Endocrinol., 32, 793-810.
25. Lanzino, M., Sisci, D., Morelli, C., Garofalo, C., Catalano, S., Casaburi, I., Capparelli, C., Giordano, C., Giordano, F., Maggiolini, M. et al. (2010) Inhibition of cyclin D1 expression by androgen receptor in breast cancer cells-identification of a novel androgen response element. Nucleic Acids Res., 38, 5351-5365.
26. Szelei, J., Jimenez, J., Soto, A.M., Luizzi, M.F. and Sonnenschein, C. (1997) Androgen-induced inhibition of proliferation in human breast cancer MCF7 cells transfected with androgen receptor. Endocrinology, 138, 1406-1412.
27. Birrell, S.N., Bentel, J.M., Hickey, T.E., Ricciardelli, C., Weger, M.A., Horsfall, D.J. and Tilley, W.D. (1995) Androgens induce divergent proliferative responses in human breast cancer cell lines. J. Steroid. Biochem. Mol. Biol., 52, 459-467.
28. Lin, H.Y., Sun, M., Lin, C., Tang, H.Y., London, D., Shih, A., Davis, F.B. and Davis, P.J. (2009) Androgen-induced human breast cancer cellproliferation is mediated by discrete mechanisms in estrogen receptor-alpha-positive and -negative breast cancer cells. J. Steroid Biochem. Mol. Biol., 113, 182-188.
29. Brawer, J., Schipper, H. and Robaire, B. (1983) Effects of long term androgen and estradiol exposure on the hypothalamus. Endocrinology, 112, 194-199.
30. Lephart, E.D. and Husmann, D.A. (1993) Altered brain and pituitary androgen metabolism by prenatal, perinatal or pre- and postnatal finasteride, flutamide or dihydrotestosterone treatment in juvenile male rats. Prog. Neuropsychopharmacol. Biol. Psychiatry, 17, 991-1003.
31. Thompson, E.R., Gorringe, K.L., Choong, D.Y., Eccles, D.M., Mitchell, G. and Campbell, I.G. (2012) Analysis of KLLN as a high-penetrance breast cancer predisposition gene. Breast Cancer Res. Treat., 134, 543-547.
32. Bieche, I., Parfait, B., Tozlu, S., Lidereau, R. and Vidaud, M. (2001) Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis, 22, 1521-1526.
33. Ghosh, P.M., Malik, S.N., Bedolla, R.G., Wang, Y., Mikhailova, M., Prihoda, T.J., Troyer, D.A. and Kreisberg, J.I. (2005) Signal transduction pathways in androgen-dependent and -independent prostate cancer cell proliferation. Endocr. Relat. Cancer, 12, 119-134.
34. Wang, Y., Mikhailova, M., Bose, S., Pan, C.X., deVere White, R.W. and Ghosh, P.M. (2008) Regulation of androgen receptor transcriptional activity by rapamycin in prostate cancer cell proliferation and survival. Oncogene, 27, 7106-7117.
35. Ihaka, S. and Gentleman, R. (1996) R: A Language for Data Analysis and Graphics. J. Comput. Graph. Stat., 5, 299-314.
36. Wang, Y., Kreisberg, J.I., Bedolla, R.G., Mikhailova, M., deVere White, R.W. and Ghosh, P.M. (2007) A 90 kDa fragment of filamin A promotes Casodex-induced growth inhibition in Casodex-resistant androgen receptor positive C4-2 prostate cancer cells. Oncogene, 26, 6061-6070.